A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
Status:
Recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label trial to assess the efficacy of melanocortin receptor
agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months
in subjects with Type II diabetic nephropathy. After six months of therapy, all subjects will
remain in trial for further assessment and undergo a diagnostic renal biopsy to assess the
effect of melanocortin therapy on diabetic histopathology at 12 months.
Phase:
Phase 2
Details
Lead Sponsor:
Palatin Technologies, Inc
Treatments:
alpha-MSH Angiotensin II Angiotensin Receptor Antagonists Angiotensin-Converting Enzyme Inhibitors